|
|
Causes of Scleroderma: Interleukins |
| |
Overview |
 Interleukins are a vital part of the pathway that regulates inflammation in the body. There are many different types of interleukins.
Interleukins play a key role in the development or progression of inflammatory conditions.
Here we focus on the interleukins that are known to be involved with systemic sclerosis (scleroderma). (Also see: What is Scleroderma? and Causes of Scleroderma)
Inflammation and Interleukins. Inflammation (Latin, inflammatio, to set on fire) is the complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. It is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue. Inflammation is not a synonym for infection. Wikipedia. |
| Interleukins are the cytokines that act specifically as mediators between leucocytes. The table shows the major source and effects of various types of interleukins. Web Books. |
Anti-TNF-a Therapies and Scleroderma |
| Off-Label Dermatologic Uses of Anti-TNF-a Therapies. Reports suggest that anti-TNF-a therapies may be effective in the treatment of numerous inflammatory skin diseases outside their currently approved indications. PubMed, J Cutan Med Surg. 2006 May 25. (Also see: Medications, Antibodies and Skin Fibrosis) |
Interleukin-1{alpha} and Scleroderma |
| A nuclear target for interleukin-1{alpha}: Interaction with the growth suppressor necdin modulates proliferation and collagen expression. Based on these findings, we propose that the constitutively up-regulated expression of pre-IL-1alpha in the nuclei of SSc fibroblasts up-regulates proliferation and matrix production of SSc fibroblasts through binding necdin, and by counteracting its effects on cell growth and collagen production. PubMed, Proc Natl Acad Sci U S A. 2003 Aug 11. |
Interleukin-6 and Scleroderma |
| Relationship between interleukin-6 (IL-6) and cardiac involvement in systemic sclerosis (SSc). These results support the role of IL-6 in the development of cardiac disease in SSc patients. PubMed, Rheumatology. 03/27/2013. (Also see: Cardiac Involvement) |
Interleukin-10 and Scleroderma |
| Analysis of the 5' flanking region of the interleukin 10 gene in patients with systemic sclerosis. IL-10 genotypes associated with high IL-10 production are under-represented in diffuse scleroderma. This may have implications in the disease pathology. PubMed, Rheumatology (Oxford). 2003 Jul 16. |
Interleukin-13 and Scleroderma |
| Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. These results suggest that TNF and IL-13 may be associated with the development of LSc. PubMed, Dermatology. 2003;207(2):141-7. |
| Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. The study confirmed that IL-13 serum levels are higher in the sera of patients with SSc, and shows for the first time the significant correlations between this serological finding and some of the main relevant SSc capillaroscopic features, leading us to believe that this cytokine not only seems to sustain the immunological and fibrotic process of SSc, but might have a role in determining the more severe microvascular lesions in this disease. PubMed, Clin Rheumatol 2003 May;22(2):102-6. |
Interleukin-17 and Scleroderma |
| Interleukin (IL)-17A promotes functional activation of systemic sclerosis (SSc) patient-derived dermal vascular smooth muscle cells by extracellular regulated protein kinases signaling pathway. IL-17A-derived from patients with SSc might be promising therapeutic targets for the treatment of SSc-related vasculopathy. PubMed, Arthritis Res Ther, 2014 Dec 31;16(6):4223. |
Interleukin-23 and Scleroderma |
| Increased Serum Interleukin 23 in Patients with Systemic Sclerosis. The results suggest that IL-23 is associated with induction of SSc and that blockade of IL-23 can be a potential therapeutic strategy in early SSc. Journal of Rheumatology. Vol 35: No 1. Jan 2008. |
Interleukin-25 and Scleroderma |
| A Jekyll and Hyde of cytokines: IL-25 both promotes and limits inflammatory diseases. The same signal responsible for promoting the type of immune responses that cause asthma and allergy can also limit the type of inflammation associated with debilitating diseases like inflammatory bowel disease, arthritis and multiple sclerosis. EurekAlert! 04/11/06. |
Interleukin-27 and Scleroderma |
| University of Pennsylvania Researchers Identify Gatekeeper Involved in Chronic Inflammatory Diseases. Researchers found that IL-27 inhibits the immune system cells that are responsible for an array of inflammatory-related diseases, including encephalitis, arthritis, Crohns disease, lupus and even sepsis. University of Pennsylvania. 08/21/06. |